TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00475098

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks
Description: treatment in lung tumours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin sodium 100 UI/Kg/OD for 12 weeks
Description: treatment in lung tumours
Study: NCT02554955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclizumab
Description: Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
Study: NCT01830543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 2.5 mg
Description: One 2.5 mg tablet twice daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 15 mg
Description: One 15 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 15 mg
Description: One 15 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 10 mg
Description: One 10 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rivaroxaban 10 mg
Description: One 10 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: Low-dose aspirin tablet once daily for twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin (ASA)
Description: Low-dose aspirin tablet once daily for twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin K antagonist (VKA)
Description: Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: One 75 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: One 75 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: One 75 mg tablet once daily for up to twelve months
Study: NCT03890263

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Pain Self-Management Support
Description: Family physicians and nurse practitioners will participate in an academic detailing session with a pharmacist that focuses on safe, evidence-based opioid deprescribing. The pharmacist will provide pre-visit recommendations for each visit with a person on high doses of opioids. The pharmacist and healthcare providers will develop a patient centered, opioid taper schedule, with follow-up at 2 to 4 week intervals to assess for efficacy and safety.~The self-management intervention will be Chronic Pain Self-management Support with Pain Science Education and Exercise (COMMENCE), which consists of 2 visits per week over 6 weeks. One visit per week is 1.5 hours in a group format. with education about self-management and pain science as well as cognitive behavioural principles. The 2nd visit each week is 30 minutes in a one-to-one format and is individually tailored to support implementation of self-management plans and development of an exercise program.
Study: NCT01830543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: One 10 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: One 10 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prasugrel
Description: One 10 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: One 90 mg tablet twice daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: One 90 mg tablet twice daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: One 90 mg tablet twice daily for up to twelve months
Study: NCT01458509

Intervention type: BEHAVIORAL
Intervention: surveys
Description: IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.

Intervention type: BEHAVIORAL
Intervention: surveys
Description: Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.

Intervention type: BEHAVIORAL
Intervention: surveys
Description: IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.

Intervention type: BEHAVIORAL
Intervention: Surveys
Description: Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
Study: NCT03284619

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imager linear accelerator
Description: The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
Study: NCT03064295

Intervention type: DEVICE
Intervention: Myocardial Perfusion Cardiac MRI.
Description: MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min

Intervention type: DEVICE
Intervention: Myocardial Perfusion Cardiac MRI.
Description: MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min

Intervention type: DEVICE
Intervention: Myocardial Perfusion Cardiac MRI.
Description: MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min

Intervention type: DRUG
Intervention: Contrast
Description: The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)

Intervention type: DRUG
Intervention: Contrast
Description: The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)

Intervention type: DRUG
Intervention: Contrast
Description: The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)

Intervention type: DRUG
Intervention: Pharmacologic Stress Agent
Description: The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min

Intervention type: DRUG
Intervention: Pharmacologic Stress Agent
Description: The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min

Intervention type: DRUG
Intervention: Pharmacologic Stress Agent
Description: The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
Study: NCT04060173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP-671
Description: ABP-671 is an investigational drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study: NCT01687413

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Study: NCT02554955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silrolimus
Description: Participants will receive sirolimus orally (3 mg/day) for 6 months.
Study: NCT03534492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: P.O.
Study: NCT01687413

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated radiation therapy (IMRT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Study: NCT02684019

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: added to propofol sedation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: added to propofol sedation
Study: NCT01325831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation(rTMS)
Description: 10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
Study: NCT03334019

Intervention type: OTHER
Intervention: blood test
Description: Data collected on general population, farmers and veterinarians though questionnaires and blood samples.
Study: NCT03569618

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tablet-based Game
Description: Tablet-based game aimed at improving processing speed and attention.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Tablet-based Game
Description: Tablet-based game aimed at improving processing speed and attention.
Study: NCT01021865

Intervention type: DRUG
Intervention: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Description: GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump

Intervention type: DRUG
Intervention: Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere
Description: GLP-1 at a rate of 1.2 pmol/kg/min~Regadenoson as a stress agent 0.4mg IV given during MCE~Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump
Study: NCT02937792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrathecal 15 mg bupivacaine
Description: spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
Study: NCT02575235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC)
Description: Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetylpyridinium Chloride (CPC)
Description: Two study groups take CPC of 1.5mg and 4.5mg daily for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Control group takes the placebo for the same period.
Study: NCT00432458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg orally on days 1-28 of 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zoledronic acid
Description: 4 mg\^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
Study: NCT01539655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 300 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 300 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 300 mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vandetanib
Description: Oral tablets, 300 mg, single dose
Study: NCT01325831

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation(rTMS)
Description: Sham repetitive transcranial magnetic stimulation(rTMS)
Study: NCT00462098

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyperbaric oxygen
Description: 40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-treated control group
Description: no change from routine care, no HBO
Study: NCT02241044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon plasma coagulation
Description: Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Distilled water
Description: Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Distilled water
Description: Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
Study: NCT04068064

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EABM training
Description: The training aims at associating gaming pictures with negative words and pictures of healthy activities with positive words. Gaming pictures are always presented with a pair of negative words. Pictures of healthy activities are always presented with a pair of positive words. Each picture is presented with a fixed pair of words. Participants will be instructed to select one word to get the most monetary reward. Specifically, in response to each gaming picture, selecting one word will have a 70% chance to get a monetary reward and the other word will have a 30% chance to get a monetary reward. A similar rationale applies to the pictures of healthy activities. The reward setting will help consolidate target associations.~Each training session includes 300 times/trials of each type of association, presented in pseudorandom way. The whole training includes 6 training sessions. Participants will receive one training session every days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham training
Description: In the control group, neutral words instead of emotional words are used. All other settings are the same with those in the intervention group
Study: NCT01539655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Oral capsules, 40 mg, multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: Oral capsules, 40 mg, multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Oral tables, 150 mg, multiple doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranitidine
Description: Oral tables, 150 mg, multiple doses
Study: NCT04619121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR-tPBM
Description: The treatment will last for 8 weeks and be bilateral and applied to the frontal areas with one application site on the left side and one on the right side (left and right forehead centered on the frontal eminences and per EEG sites on F3 and F4). Energy is administered with a radiation wavelength of 830 nm. The duration of irradiation is from 20 minutes at each application site (the 2 sites are irradiated at the same time which is equivalent to 20 minutes of total time) to 40 minutes at each site, up to 2 times per day. The treatment will follow these specifications: PBM (IR) irradiance of 33.2 mW/cm2, each treatment window area is 28.7 cm2; PBM (IR) fluence of up to 60 Joules/cm2; energy delivered per session per device up to 1.72 kJ for a total of up to 3.44 kJ.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham device
Description: The sham device is completely identical in appearance, but only emits neglectable energy to the brain.
Study: NCT01107275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: intradermal vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rabies vaccine
Description: intradermal vaccination
Study: NCT02850055

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: 1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific Manual Therapy
Description: 1. Leaflet care and health habits of the temporomandibular joint.~2. Program of cranio-cervical and temporomandibular exercises.~3. Massage of the cervical muscles and self care document for home.~4. Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles.
Study: NCT03753152

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental
Description: Neuramis® Deep Lidocaine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: comparator
Description: YVOIRE® Volume Plus
Study: NCT00831233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
Study: NCT04417647

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VZ powder (purified clinoptilolite)
Description: VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VZ powder (purified clinoptilolite)
Description: VZ powder will be applied topically to the open surface of the verum treatment-assigned wound to cover the entire wound area. Following each VZ application, wounds will be protected by wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care (SoC)
Description: wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard of care (SoC)
Description: wound cleansing (0.9% saline solution) and wound dressing (non-adhesive wound dressing (AdapticTM) and conventional protective Mepore® dressing) will be applied to the SoC-assigned wound.